JAK2/3 Antikörper (pTyr939, pTyr966)
Kurzübersicht für JAK2/3 Antikörper (pTyr939, pTyr966) (ABIN7229208)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- pTyr939, pTyr966
-
Verwendungszweck
- JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody
-
Spezifität
- The antibody detects endogenous levels of JAK2/3 when Phospho occurs at Tyr966/939(human) or Tyr966/935(mouse/rat) , It doesn't react with total protein.
-
Aufreinigung
- The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen
-
Immunogen
- Synthesized peptide derived from part region of human JAK2/3 (Phospho-Tyr966/939) Antibody protein at AA range: T966
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:1000), ICC (1:200). Not yet tested in other applications.
-
Kommentare
-
Primary Antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS, pH 7.4, containing 0.02 % Sodium Azide as preservative and 50 % Glycerol as stabilizer.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
-
-
- JAK2/3 (Janus Kinase 2/3 (JAK2/3))
-
Andere Bezeichnung
- JAK2/3
-
Hintergrund
- Rabbit Anti-JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody,Tyrosine-protein kinase JAK2/JAK3, Janus kinase 2/Janus kinase 3, JAK-2/JAK-3,JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.,JAK2/3
-
Gen-ID
- 1132, 1124
Target
-